Zymo Research is a globally established biotechnology company and industry leader in the fields of epigenetics, microbiomics and the emerging Next-Gen Sequencing space. With international facilities and a global distribution network, Zymo Research enables researchers in academia and the biomedical field to make cutting-edge discoveries all over the world. While the company provides some of the most technologically advanced products in the industry, everything is driven by the fundamental belief that “the beauty of science is to make things simple.”
Vffice Inc
VFFICE is a Microsoft Cloud Solution Partner specializing in Enterprise Software, including ERP, CRM, BI, and Custom Development for the Pharma and Life Sciences Industry. We serve clients globally promoting growth and digital transformation with a dedicated focus on the Microsoft platform and AI. | VFFICE is a Microsoft Cloud Solution Partner delivering innovative, Microsoft‑based enterprise solutions for the Pharma and Life Sciences industry. We enhance traditional ERP with advanced data analytics, automation, and embedded AI to support regulatory compliance, reporting, batch and inventory traceability, quality management, formulation control, LIMS integration, and real‑time financial and operational visibility. Our solutions empower pharmaceutical and life sciences organizations across R&D, drug discovery, diagnostics, biomanufacturing, and distribution to accelerate innovation, improve operational excellence, and drive digital transformation. With deep expertise in ERP, CRM, BI, and custom development on the Microsoft platform, VFFICE serves clients globally, helping them scale with confidence in highly regulated environments.
Vacino Biotech Co., Ltd.
Vacino Biotech focuses on innovations for HLA-peptide based vaccine (9-mer peptide), nucleic acid medicine (microRNA) and brain delivery technology (targeting peptide) for the indication of infectious disease, neurodegenerative disease and oncology. Core products: Oral universal COVID vaccine against SARS-CoV-2 variants A microRNA-based anti-neuroinflammation therapeutics A brain shuttled anti-Her2 antibody for treating the peripheral and intracranial tumors. An oral bioavailable brain-targeting LNP for delivering the oligonucleotide and large molecule therapeutics Show less Description (NOTE: Given time constraints & strategic priorities, we will not be meeting with CMOs, CROs, service companies, etc. at the meeting) Founded in July 2020, Vacino Biotech is committed to the development of novel nucleic acid drugs and universal vaccines. With the self-developed next-generation vaccine design SED technology, we have invested in the development of COVID-19 T-cell vaccine products to solve the situation of rapid mutation of the new coronavirus variants. In addition, it has invested in the development of nucleic acid drugs for the treatment of Alzheimer’s disease and a cutting-edge efficient brain delivery technology to increase the content of brain treatment drugs and prevent the occurrence of diseases at an early stage. ● Core products and platform technology Oral universal COVID-19 vaccine: VACINO-CO is a novel oral universal antigen vaccine designed to protect against most COVID-19 viruses and related variants. Through the activation of T cells, it can eliminate virus-infected cells, which can effectively inhibit recurrence and the phenomenon of seroconversion. The innovative and convenient oral dosage form can be applied to the elderly and children in vulnerable groups to obtain safer and effective immunity, safe and effective immune protection of the population. It is currently about to enter human clinical trials. MicroRNA-based Alzheimer’s Disease Drug Developments: Patented Vacino-ADmir is a microRNA-based drug that inhibits neuroinflammation through the PD1/PDL1 mechanism associated with inflammation and can be treated from the source of the disease, which is different from the symptomatic treatment on the market. It can be applied to dementia and neuroinflammation-related diseases. GMP manufacturing is currently underway. High-Performance Brain Delivery Platform Technology: The patented Vacino-BT target peptide can be co-transported by binding to transferrin receptors through transcytosis, with a brain delivery rate of more than 20 % a 1-hour post-injection, which is far superior to other brain delivery technologies on the market. At present, it has been successfully applied to antibodies and lipid nanoparticles. GoBrain LNP: Based VBT technology, we developed VBT-lipid conjugates that can enable LNP having brain targeting capability. HerBrain and eHerbrain platform: Based on VBT technology, we developed chemically modified anti-Her2 antibody and novel DNA-engineered anti-Her2 antibody, which allows brain shuttle capability and tissue penetration.
Turbine
Turbine is virtualizing biological experiments with AI to accelerate drug discovery and improve clinical translatability. Using its foundational virtual cell model powered by its lab-in-the-loop, Turbine creates virtual copies of experimental assays. Running experiments at computational speed and scale allows researchers to test millions of ideas, beyond physical lab constraints, to understand biological drivers of disease. Working with scientists at leading biopharma like MSD (Merck & Co.), AstraZeneca and Bayer, Turbine’s virtual assays have rationalized experiments across more than 30 discovery programs. Backed by leading tech and industry investors like Accel, MSD Global Health Innovation Fund, Interactive Venture Partners and Beiersdorf, Turbine is turning biology into an engineering discipline.
Tunnell Consulting
For over 60 years, Tunnell has provided both expert talent and consulting services to clients including Biopharmas, CDMOs, the US Government, incubators, investors and NGOs. We have experience across multiple platforms – including large molecule, vaccines, cell and gene therapy and small molecule – and our subject matter expertise focuses on regulatory, quality, GxP, pre-clinical/clinical, supply chain, manufacturing, CMC and product launch. To learn more, visit us online at http://www.tunnellconsulting.com.
The National Institute for Health and Care Research (NIHR)
The NIHR Life Sciences Industry Hub is your entry point to England’s integrated clinical research system, with coordinated access to UK-wide capability. The Industry Hub’s support is free of charge, funded by the UK Government, and designed to make the UK a globally competitive destination for commercial clinical research. We provide: Single national entry to NIHR – One conversation provides access to our entire integrated commercial trials pathway. Dedicated operational leadership – A named national lead coordinates delivery and manages dependencies across the system. Reliable, data-enabled feasibility – Coordinated once, using real-time capability and capacity to improve predictability. Smarter site selection – Intelligent study placement across health and care settings for speed, quality and performance. Faster start-up – Coordinated oversight of costing, contracting and assurance. Active performance management and escalation – Real-time oversight of set-up and recruitment, with clear escalation routes and time-bound resolution. Inclusive, scalable recruitment – Approaches that improve reach, diversity and reliability, including digitally-enabled and hybrid delivery models. Strategic partnership opportunities – Portfolio-level engagement and longer-term collaboration with the NIHR research system.
The Hong Kong Polytechnic University
With 85 years of proud tradition and ranking among the world’s top 100 institutions, The Hong Kong Polytechnic University (PolyU) aspires to be a leading university with world-class research and education. Our holistic professional education, which embraces new technologies, entrepreneurship, and service-learning, aims to nurture graduates who not only possess a competitive edge in their disciplinary knowledge, but also develop into socially responsible leaders. As a university with a strong emphasis on societal impact, PolyU is devoted to providing interdisciplinary solutions for major social challenges through advanced research and knowledge transfer activities. Our innovations have opened up new horizons in space, improved health and well-being, boosted economic efficiency, and fostered sustainability for a better world. Our strong culture of knowledge transfer and entrepreneurship helps transform our research breakthroughs into real-world applications. Looking to the future, PolyU will continue its pursuit of excellence, cultivating talent who serve society with passion, and contributing to the development of Hong Kong as an international innovation and technology hub in the Greater Bay Area. We will carry on manifesting the spirit of the University’s Motto: To learn and to apply, for the benefit of mankind. | With 86 years of proud tradition and ranking among the world’s top 100 institutions, The Hong Kong Polytechnic University (PolyU) aspires to be a leading university with world-class research and education. Our holistic professional education, which embraces new technologies, entrepreneurship, and service-learning, aims to nurture graduates who not only possess a competitive edge in their disciplinary knowledge, but also develop into socially responsible leaders. As a university with a strong emphasis on societal impact, PolyU is devoted to providing interdisciplinary solutions for major social challenges through advanced research and knowledge transfer activities. Our innovations have opened up new horizons in space, improved health and well-being, boosted economic efficiency, and fostered sustainability for a better world. Our strong culture of knowledge transfer and entrepreneurship helps transform our research breakthroughs into real-world applications. Looking to the future, PolyU will continue its pursuit of excellence, cultivating talent who serve society with passion, and contributing to the development of Hong Kong as an international innovation and technology hub in the Greater Bay Area. We will carry on manifesting the spirit of the University’s Motto: To learn and to apply, for the benefit of mankind. | The Hong Kong Polytechnic University (PolyU) aspires to be an innovative world-class university that pursues excellence in education, research and knowledge transfer. Driven by its motto, “To learn and to apply, for the benefit of mankind”, the University nurtures socially responsible professionals and leaders and pursues world-leading research and innovation for societal benefits. | With 85 years of proud tradition and ranking among the world’s top 100 institutions, The Hong Kong Polytechnic University (PolyU) aspires to be a leading university with world-class research and education. We strive in inter-disciplinary research and impactful innovations to address real-world challenges.